Hypoglycemia as a Treatment Strategy in cancer patients.

Hypoglycemia in cancer treatment is either

metabolic, tumor-induced complication—
- known as Non-Islet Cell Tumor Hypoglycemia (NICTH)—

experimental therapeutic strategy to starve cancer cells of glucose.
- Cancer cells rely heavily on glucose for energy (the Warburg effect), making them susceptible to damage when blood sugar is lowered.

The Science of Tumor-Induced Hypoglycemia (NICTH)

Mechanism: Certain tumors, such as liver cancer or mesothelioma, overproduce a precursor to insulin-like growth factor II ("big" IGF-II).
Paraneoplastic Effect: This abnormal IGF-II binds to insulin receptors and suppresses normal glucose production, leading to severe low blood sugar.
Other Causes: Tumors may destroy liver or adrenal tissues, reducing the body's ability to produce or store glucose.
Management: Treatment includes corticosteroids (e.g., dexamethasone), which increase blood glucose and inhibit IGF-II production.

Hypoglycemia as a Treatment Strategy

Targeting Metabolism: Because cancer cells have defective mitochondria and high glycolytic rates, creating a low-glucose environment can induce apoptosis (cell death).
Sensitizing Agents: Combining low-glucose states (or intermittent fasting) with drugs like metformin has been shown to break down the metabolic flexibility of tumors.
Chemotherapy Boost: Insulin-induced hypoglycemia can make cancer cells more susceptible to chemotherapy, potentially lowering the required dosage. Applied to Insulin Dependent diabetics only.
Safety: Experimental approaches, such as using extracorporeal membrane oxygenation (ECMO), are being explored to maintain severe hypoglycemia without damaging vital organs.

Key Considerations

Symptoms: Fatigue, dizziness, perspiration, and palpitations can occur when blood glucose drops, often requiring immediate, cautious management.
Diagnosis: Essential tools include measuring IGF-2 levels, insulin levels, and using imaging to locate the tumor causing the metabolic shift

Recent Posts